These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33372105)

  • 1. Next generation sequencing for detection of
    Batra U; Nathany S; Sharma M; Jain P; Mehta A
    J Clin Pathol; 2022 Mar; 75(3):164-167. PubMed ID: 33372105
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
    Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
    Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Advantage of Targeted Next-Generation Sequencing over qPCR in Testing for Druggable
    Szpechcinski A; Moes-Sosnowska J; Skronska P; Lechowicz U; Pelc M; Szolkowska M; Rudzinski P; Wojda E; Maszkowska-Kopij K; Langfort R; Orlowski T; Sliwinski P; Polaczek M; Chorostowska-Wynimko J
    Int J Mol Sci; 2024 Jul; 25(14):. PubMed ID: 39063150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of epidermal growth factor receptor mutation detection turnaround times and concordance among real-time polymerase chain reaction, high-throughput next-generation sequencing and the Biocartis Idylla™ platforms in non-small cell lung carcinomas.
    Sharma S; Satapathy A; Aggarwal A; Dewan A; Jain E; Katara R; Kumar V; Pal R; Pandey S; Naidu MM; Kini L; Pradhan D; Mohanty SK
    Pathol Res Pract; 2021 Apr; 220():153394. PubMed ID: 33706124
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients.
    He C; Wei C; Wen J; Chen S; Chen L; Wu Y; Shen Y; Bai H; Zhang Y; Chen X; Li X
    J Cancer Res Clin Oncol; 2022 Feb; 148(2):321-330. PubMed ID: 34693477
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
    Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
    Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rare epidermal growth factor receptor gene alterations in non-small cell lung cancer patients, tyrosine kinase inhibitor response and outcome analysis.
    Mehta A; Vasudevan S
    Cancer Treat Res Commun; 2021; 28():100398. PubMed ID: 34052672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the SuperARMS and ARMS for detecting EGFR mutations in liquid-based cytology specimens from NSCLC patients.
    Wu W; Cao Z; Zhang W; Zhang L; Hou L; Wu C
    Diagn Pathol; 2020 Jan; 15(1):9. PubMed ID: 32005253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Detection of circulating tumor DNA in epidermal growth factor receptor-TKI relapsed non-small cell lung cancer patients using next-generation sequencing and an analysis of the resistant mechanisms].
    Li Y; Zhang FS; Guo L; Ying JM
    Zhonghua Bing Li Xue Za Zhi; 2018 Dec; 47(12):904-909. PubMed ID: 30522169
    [No Abstract]   [Full Text] [Related]  

  • 10. Mutation Spectrum of
    Mao L; Zhao W; Li X; Zhang S; Zhou C; Zhou D; Ou X; Xu Y; Tang Y; Ou X; Hu C; Ding X; Luo P; Yu S
    Pathol Oncol Res; 2021; 27():602726. PubMed ID: 34257561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High MAF of EGFR mutations and high ratio of T790M sensitizing mutations in ctDNA predict better third-generation TKI outcomes.
    Li Y; Zhang F; Yuan P; Guo L; Jianming Y; He J
    Thorac Cancer; 2020 Jun; 11(6):1503-1511. PubMed ID: 32285618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
    Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
    Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three new disease-progression modes in NSCLC patients after EGFR-TKI treatment by next-generation sequencing analysis.
    Wei Y; Shen K; Lv T; Wang X; Li C; Fan H; Lv Y; Liu H; Song Y
    Lung Cancer; 2018 Nov; 125():43-50. PubMed ID: 30429037
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Co-occurring genetic alterations and primary EGFR T790M mutations detected by NGS in pre-TKI-treated NSCLCs.
    Tang Y; Che N; Yu Y; Gao Y; Shi H; Feng Q; Wei B; Ma L; Gao M; Ma J; Lin D
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):407-416. PubMed ID: 31696302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance.
    Zugazagoitia J; Gómez-Rueda A; Jantus-Lewintre E; Isla D; Camps C; Ramos I; Trigo JM; Bernabé R; Juan-Vidal O; Sanchez-Torres JM; García-Campelo R; Provencio M; Felip E; de Castro J; Faull I; Lanman RB; Ponce-Aix S; Paz-Ares L; Garrido P
    Lung Cancer; 2019 Aug; 134():72-78. PubMed ID: 31319999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-Free DNA Next-Generation Sequencing Prediction of Response and Resistance to Third-Generation EGFR Inhibitor.
    Helman E; Nguyen M; Karlovich CA; Despain D; Choquette AK; Spira AI; Yu HA; Camidge DR; Harding TC; Lanman RB; Simmons AD
    Clin Lung Cancer; 2018 Nov; 19(6):518-530.e7. PubMed ID: 30279111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Picoliter-Droplet Digital Polymerase Chain Reaction-Based Analysis of Cell-Free Plasma DNA to Assess EGFR Mutations in Lung Adenocarcinoma That Confer Resistance to Tyrosine-Kinase Inhibitors.
    Seki Y; Fujiwara Y; Kohno T; Takai E; Sunami K; Goto Y; Horinouchi H; Kanda S; Nokihara H; Watanabe S; Ichikawa H; Yamamoto N; Kuwano K; Ohe Y
    Oncologist; 2016 Feb; 21(2):156-64. PubMed ID: 26768482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
    Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
    Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk stratification of EGFR
    Christopoulos P; Kirchner M; Roeper J; Saalfeld F; Janning M; Bozorgmehr F; Magios N; Kazdal D; Volckmar AL; Brückner LM; Bochtler T; Kriegsmann M; Endris V; Penzel R; Kriegsmann K; Eichhorn M; Herth FJF; Heussel CP; El Shafie RA; Schneider MA; Muley T; Meister M; Faehling M; Fischer JR; Heukamp L; Schirmacher P; Bischoff H; Wermke M; Loges S; Griesinger F; Stenzinger A; Thomas M
    Lung Cancer; 2020 Oct; 148():105-112. PubMed ID: 32871455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequently used quantitative polymerase chain reaction-based methods overlook potential clinically relevant genetic alterations in epidermal growth factor receptor compared with next-generation sequencing: a retrospective clinical comparison of 1839 lung adenocarcinomas.
    Tønnesen E; Lade-Keller J; Stougaard M
    Hum Pathol; 2021 Sep; 115():67-75. PubMed ID: 34153308
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.